SARS-CoV-2 antibody tests
The serology tests offered by medac for the specific detection of anti-SARS-CoV-2 IgM and IgG antibodies are the first CE IVD-certified tests worldwide. The recombinant, highly specific N and S antigens used guarantee optimal sensitivity even towards neutralising antibodies.
|MAGLUMI® 2019nCoV-IgM Antibody Test (CLIA)||SARS CoV-2 (S and N antigen)|
|MAGLUMI® SARS-CoV-2 S-RBD IgG Antibody Test (CLIA)||SARS CoV-2 (S-RBD antigen)|
The chemiluminescence method supports the high sensitivity and specifity, and allows for a large linear measuring range for the quantification of the IgG antibodies. Furthermore, the IgM test makes use of the µ‑capture system, which has been employed successfully by medac since the 1980s, and which guarantees high sensitivity at the same time as high specifity.
Random access device platform
The chemiluminescence imunoassays (CLIA) are handled in a fully automated process and provide initial results after just 35 minutes. Compact table-top devices or larger, stand-alone Maglumi systems by our exclusive partner Snibe are available for automation purposes. Depending on the tests used, up to 280 results an hour can be obtained.
In addition to the SARS-CoV-2 antibody tests, the portfolio comprises up to 100 other parameters which can be processed at the same time with the Maglumi systems. This includes e.g. inflammation parameters such as CRP, PCT, interleukin-6, or cardiological parameters which also play a role in connection with SARS-CoV-2 diagnostics.
Our quality standards
We took as much time as was needed to be able to offer these tests so they meet our quality standards as well as to ensure reliability of supply. The high quality of the tests has meanwhile been confirmed in several independent studies.
Contact our experienced team for a consultation so that we can meet your specific laboratory needs in the best way possible.
Watch the Maglumi 800 ® do it.